Moderna MRNA
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 1st percentile, 5-year average 0.3x
Near the top of its 5-year range · 99th percentile, 5-year average 3.3x
#5005 of 5311 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 6.1x
#4834 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 13.09 | – | 3.29 | 99% (pricier than usual) | #5005 of 5311 (1 = cheapest) |
| PE | -27.78 | -30.62 | 0.25 | 1% (cheaper than usual) | – |
| PS | 39.73 | 46.39 | 6.14 | 99% (pricier than usual) | #4834 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on MRNA.
Sign in to join the discussion.